OBJECTIVE: Laminin-332, a marker of epithelial-mesenchymal transition, is composed of a heterotrimer of α3, β3 and γ2 chains that regulates cell adhesion and migration. This study aimed to disclose the respective clinical significance of laminin β3 immunoexpression in colorectal cancer as a prognostic factor and a predictive marker of chemoresistance. METHODS: Tissue specimens from 323 Stage II and 232 Stage III colorectal cancer patients who underwent curative resection were assessed using laminin β3 immunostaining. RESULTS: Among Stage III colorectal cancer patients, comparisons of 5-year disease-free survival rates revealed a poorer prognosis for the laminin β3-high group than for the laminin β3-low group (52.3 vs. 70.7%, P = 0.038), while there was no significant difference among Stage II patients. Among laminin β3-low Stage III patients, those who received adjuvant chemotherapy showed marginally better disease-free survival than those who did not receive it (75.8 vs. 62.8%; P = 0.096). Furthermore, multivariate analysis corroborated a distinct benefit of adjuvant chemotherapy in laminin β3-low patients (P = 0.035; hazard risk ratio = 1.66). Analyses of the laminin β3-high group, however, failed to show significance. CONCLUSIONS: Laminin β3 chain immunoreactivity was a poor prognostic factor for Stage III colorectal cancer patients, and laminin β3-high patients of Stage III colorectal cancer derived no survival benefit from adjuvant chemotherapy.
OBJECTIVE: Laminin-332, a marker of epithelial-mesenchymal transition, is composed of a heterotrimer of α3, β3 and γ2 chains that regulates cell adhesion and migration. This study aimed to disclose the respective clinical significance of laminin β3 immunoexpression in colorectal cancer as a prognostic factor and a predictive marker of chemoresistance. METHODS: Tissue specimens from 323 Stage II and 232 Stage III colorectal cancerpatients who underwent curative resection were assessed using laminin β3 immunostaining. RESULTS: Among Stage III colorectal cancerpatients, comparisons of 5-year disease-free survival rates revealed a poorer prognosis for the laminin β3-high group than for the laminin β3-low group (52.3 vs. 70.7%, P = 0.038), while there was no significant difference among Stage II patients. Among laminin β3-low Stage III patients, those who received adjuvant chemotherapy showed marginally better disease-free survival than those who did not receive it (75.8 vs. 62.8%; P = 0.096). Furthermore, multivariate analysis corroborated a distinct benefit of adjuvant chemotherapy in laminin β3-low patients (P = 0.035; hazard risk ratio = 1.66). Analyses of the laminin β3-high group, however, failed to show significance. CONCLUSIONS: Laminin β3 chain immunoreactivity was a poor prognostic factor for Stage III colorectal cancerpatients, and laminin β3-high patients of Stage III colorectal cancer derived no survival benefit from adjuvant chemotherapy.
Authors: Jennifer R Ribeiro; Hilary M Gaudet; Mehreen Khan; Christoph Schorl; Nicole E James; Matthew T Oliver; Paul A DiSilvestro; Richard G Moore; Naohiro Yano Journal: Front Oncol Date: 2018-01-22 Impact factor: 6.244
Authors: Dimakatso Alice Senthebane; Arielle Rowe; Nicholas Ekow Thomford; Hendrina Shipanga; Daniella Munro; Mohammad A M Al Mazeedi; Hashim A M Almazyadi; Karlien Kallmeyer; Collet Dandara; Michael S Pepper; M Iqbal Parker; Kevin Dzobo Journal: Int J Mol Sci Date: 2017-07-21 Impact factor: 5.923
Authors: Vladimir V Galatenko; Diana V Maltseva; Alexey V Galatenko; Sergey Rodin; Alexander G Tonevitsky Journal: BMC Med Genomics Date: 2018-02-13 Impact factor: 3.063